Mark Olfson1, Marissa King2, Michael Schoenbaum3. 1. 1 Department of Psychiatry, College of Physicians and Surgeons, Columbia University and New York State Psychiatric Institute , New York, New York. 2. 2 Yale School of Management, New Haven, Connecticut. 3. 3 Office of Science Policy, Planning, and Communications, National Institute of Mental Health, National Institutes of Health , Bethesda, Maryland.
Abstract
OBJECTIVE: To describe national stimulant treatment patterns among young people focusing on patient age and prescribing specialty. METHODS: Stimulant prescriptions to patients aged 3-24 were analyzed from the 2008 IMS LifeLink LRx Longitudinal Prescription database (n = 3,147,352), which includes 60% of all U.S. retail pharmacies. A subset of young people from 2009 with service claims (n = 197,654) were also analyzed. Denominators were adjusted to generalize estimates to the U.S. POPULATION: Population percentages filling ≥1 stimulant prescription during the study year by sex and age group (younger children, 3-5 years; older children, 6-12 years; adolescents, 13-18 years; and young adults, 19-24 years) were determined. Percentages prescribed stimulants by psychiatrists, child and adolescent psychiatrists, pediatricians, and other physicians were also determined along with percentages that were treated for a long or short duration; coprescribed other psychotropic medications; used psychosocial services; and received clinical psychiatric diagnoses. RESULTS: Population percentages with any stimulant use varied across younger children (0.4%), older children (4.5%), adolescents (4.0%), and young adults (1.7%). Among children and adolescents, males were over twice as likely as females to receive stimulants. Percentages of stimulant-treated young people with ≥1 stimulant prescription from a child and adolescent psychiatrist varied from younger children (19.1%), older children (17.1%), and adolescents (18.2%) to young adults (10.1%), and these percentages increased among those who were also prescribed other psychotropic medications: young children (31.0%), older children (37.9%), adolescents (35.1%), and young adults (15.8%). Antipsychotics were the most commonly coprescribed class to stimulant-treated younger (15.0%) and older children (11.8%), while antidepressants were most commonly coprescribed to adolescents (17.5%) and young adults (23.9%). CONCLUSIONS: Stimulant treatment peaks during middle childhood, especially for boys. For young people treated with stimulants, including younger children, low rates of treatment by child and adolescent psychiatrists highlight difficulties with access to specialty mental health services.
OBJECTIVE: To describe national stimulant treatment patterns among young people focusing on patient age and prescribing specialty. METHODS: Stimulant prescriptions to patients aged 3-24 were analyzed from the 2008 IMS LifeLink LRx Longitudinal Prescription database (n = 3,147,352), which includes 60% of all U.S. retail pharmacies. A subset of young people from 2009 with service claims (n = 197,654) were also analyzed. Denominators were adjusted to generalize estimates to the U.S. POPULATION: Population percentages filling ≥1 stimulant prescription during the study year by sex and age group (younger children, 3-5 years; older children, 6-12 years; adolescents, 13-18 years; and young adults, 19-24 years) were determined. Percentages prescribed stimulants by psychiatrists, child and adolescent psychiatrists, pediatricians, and other physicians were also determined along with percentages that were treated for a long or short duration; coprescribed other psychotropic medications; used psychosocial services; and received clinical psychiatric diagnoses. RESULTS: Population percentages with any stimulant use varied across younger children (0.4%), older children (4.5%), adolescents (4.0%), and young adults (1.7%). Among children and adolescents, males were over twice as likely as females to receive stimulants. Percentages of stimulant-treated young people with ≥1 stimulant prescription from a child and adolescent psychiatrist varied from younger children (19.1%), older children (17.1%), and adolescents (18.2%) to young adults (10.1%), and these percentages increased among those who were also prescribed other psychotropic medications: young children (31.0%), older children (37.9%), adolescents (35.1%), and young adults (15.8%). Antipsychotics were the most commonly coprescribed class to stimulant-treated younger (15.0%) and older children (11.8%), while antidepressants were most commonly coprescribed to adolescents (17.5%) and young adults (23.9%). CONCLUSIONS: Stimulant treatment peaks during middle childhood, especially for boys. For young people treated with stimulants, including younger children, low rates of treatment by child and adolescent psychiatrists highlight difficulties with access to specialty mental health services.
Authors: Craig F Garfield; E Ray Dorsey; Shu Zhu; Haiden A Huskamp; Rena Conti; Stacie B Dusetzina; Ashley Higashi; James M Perrin; Rachel Kornfield; G Caleb Alexander Journal: Acad Pediatr Date: 2012-02-10 Impact factor: 3.107
Authors: Mark Wolraich; Lawrence Brown; Ronald T Brown; George DuPaul; Marian Earls; Heidi M Feldman; Theodore G Ganiats; Beth Kaplanek; Bruce Meyer; James Perrin; Karen Pierce; Michael Reiff; Martin T Stein; Susanna Visser Journal: Pediatrics Date: 2011-10-16 Impact factor: 7.124
Authors: Mary Margaret Gleason; Helen Link Egger; Graham J Emslie; Laurence L Greenhill; Robert A Kowatch; Alicia F Lieberman; Joan L Luby; Judith Owens; Lawrence D Scahill; Michael S Scheeringa; Brian Stafford; Brian Wise; Charles H Zeanah Journal: J Am Acad Child Adolesc Psychiatry Date: 2007-12 Impact factor: 8.829
Authors: Julie M Zito; Daniel J Safer; Satish Valluri; James F Gardner; James J Korelitz; Donald R Mattison Journal: J Child Adolesc Psychopharmacol Date: 2007-04 Impact factor: 2.576
Authors: Ryan S Sultan; Christoph U Correll; Michael Schoenbaum; Marrisa King; John T Walkup; Mark Olfson Journal: J Child Adolesc Psychopharmacol Date: 2018-01-29 Impact factor: 2.576